Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377585 · ClinicalTrials.gov registry record · Phase 2
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,350
- Enrollment target
NCT00377585 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,350 participants.
The verdict
NCT00377585, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,350 participants
- Enrollment target
Study Summary
The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above. A control group in younger adults aged 18 to 40 years was included.
Interventions
- BIOLOGICAL Fluarix
- BIOLOGICAL adjuvanted influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,350 participants |
| Start Date | 2006-09-22 |
| Est. Completion | 2007-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00377585
The ClinicalTrials.gov registry entry for NCT00377585 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3,350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluarix is the first listed.
NCT00377585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00377585 about?
NCT00377585 is a clinical study titled "Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population". The study is designed to demonstrate a meaningful difference in immunogenicity between the candidate adjuvanted vaccine compared to the licensed Fluarix vaccine in subjects aged 50 years and above. A control group in younger adults aged 18 to 40 years was included.
What is the current status of trial NCT00377585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,350 participants. The study started on 2006-09-22. Estimated completion is 2007-01-30.
What interventions are being tested in trial NCT00377585?
The interventions under investigation include: Fluarix (BIOLOGICAL), adjuvanted influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00377585?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.